[
  {
    "objectID": "SVEPM_slides.html#surveillance-programmes-of-interest-for-this-research",
    "href": "SVEPM_slides.html#surveillance-programmes-of-interest-for-this-research",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Surveillance programmes of interest for this research",
    "text": "Surveillance programmes of interest for this research\n\nObjective of surveillance: identify dairy herds with at least one infected animal\nSystematic herd testing:\n\nevery herd tested\nfrom once to several times per year\n\nOverall objective can vary: control, eradication or proof of freedom from infection\nMany such programmes use ELISA testing on bulk tank milk1\n\nDenmark\\(^2\\): BVDV, Salmonella Dublin\nFinland\\(^3\\): BVDV, BoHV-1, Leukosis\nThe Netherlands\\(^4\\): BVDV, BoHV-1, Leptospira Hardjo, Salmonella Dublin, Neospora caninum\n\n\nNobrega et al., 2023a, 2023b ; 2. Nielsen et al., 2021 ; 3. Autio et al., 2021 ; 4. Santman-Berends et al., 2021"
  },
  {
    "objectID": "SVEPM_slides.html#challenges-with-using-pooled-samples",
    "href": "SVEPM_slides.html#challenges-with-using-pooled-samples",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Challenges with using pooled samples",
    "text": "Challenges with using pooled samples\n\nOverall question: how to determine the true herd status from a given test results?\nNeed to know test characteristics (Se / Sp)\nTheoretical gold standard: presence of a single infected (or seropositive) animal within the herd but…\nFactors specific to the programme could lead to test results having slightly different interpretations depending on the context:\n\nIndividual animal contribution varies with herd size leading to lower probability of detecting a single infected animal in larger herds\nReplacement rate affects seropositivity dynamics\n\nWe could use latent class models to determine test characteristics but:\n\nrequire performing several tests at the same time\ndo not account for temporal correlations in test results"
  },
  {
    "objectID": "SVEPM_slides.html#incorporating-test-uncertainty-and-temporal-correlation-in-determining-true-herd-status-with-hmms",
    "href": "SVEPM_slides.html#incorporating-test-uncertainty-and-temporal-correlation-in-determining-true-herd-status-with-hmms",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Incorporating test uncertainty and temporal correlation in determining true herd status with HMMs",
    "text": "Incorporating test uncertainty and temporal correlation in determining true herd status with HMMs\n\nHidden Markov Models (HMMs) are statistical models representing a latent, time-dependent variable:\n\nLatent and discrete: The variable of interest (e.g., herd infection status: infected/uninfected) is not observed directly\nImperfectly measured: Observations (test results) are subject to error, with sensitivity and specificity less than 1\nMarkovian dynamics: Time is discrete; the true status at each time point depends only on the status at the previous time point."
  },
  {
    "objectID": "SVEPM_slides.html#the-stoc-free-model-an-hmm-for-surveillance",
    "href": "SVEPM_slides.html#the-stoc-free-model-an-hmm-for-surveillance",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "The STOC free model: an HMM for surveillance",
    "text": "The STOC free model: an HMM for surveillance\n\nModel developed as part of the STOC free project:\n\nto predict herd-level probability of freedom from infection\nfrom longitudinal surveillance data\n\nInput: binary longitudinal test results as collected in surveillance programmes\nOutputs: test characteristics, herd-level probability of infection\nMonthly time step\nBayesian framework, model implemented in Stan, packaged as the STOCfree R package\nPriors placed on test characteristics and monthly transition probabilities"
  },
  {
    "objectID": "SVEPM_slides.html#the-problem-with-binary-data",
    "href": "SVEPM_slides.html#the-problem-with-binary-data",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "The problem with binary data",
    "text": "The problem with binary data\n\nTest results almost always discretised into negative/positive\nLoss of valuable information: results far from the cut-off carry less uncertainty than those close to it\nSeveral attempts at modelling continuous test results as mixtures of statistical distributions1\nWe developed an HMM that incorporates continuous test results\n\ne.g., Branscum et al., 2006 ; Choi et al., 2006 ; Yang et al., 2022 ; Wang et al., 2024"
  },
  {
    "objectID": "SVEPM_slides.html#an-hmm-integrating-continuous-test-results",
    "href": "SVEPM_slides.html#an-hmm-integrating-continuous-test-results",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "An HMM integrating continuous test results",
    "text": "An HMM integrating continuous test results\n\n\n\nSimilarities with the STOC free model:\n\nLatent status (\\(S\\)) with Markovian dynamics\nMonthly time step\n\nDifference:\n\nTest results (\\(y\\)) modelled as a mixture of 2 normal distributions instead of binary outcomes"
  },
  {
    "objectID": "SVEPM_slides.html#objectives-of-this-study",
    "href": "SVEPM_slides.html#objectives-of-this-study",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Objectives of this study",
    "text": "Objectives of this study\n\nUsing simulated data:\n\nCompare parameter estimation between the discrete and continuous HMMs\n\nUsing real BVD surveillance data from Brittany, France (2014 - 2020):\n\nDetermine the parameters of the distributions of BTM antibody tests results (\\(\\mu\\)s, \\(\\sigma\\)s)\nAssess the dynamics of seroconversion over time (\\(\\tau_1, \\tau_2\\))"
  },
  {
    "objectID": "SVEPM_slides.html#simulated-scenarios",
    "href": "SVEPM_slides.html#simulated-scenarios",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Simulated scenarios",
    "text": "Simulated scenarios\n\n6 scenarios were simulated to reflect a range of plausible values for the different model parameters\n\n\n\n\n\n\n\n\nSc\n\\(\\tau_1\\)\n\\(\\tau_2\\)\n\\(\\mu_0\\)\n\\(\\mu_1\\)\nCut-off\nSe\nSp\n\n\n\n\n1\n0.1\n0.85\n25\n75\n50.0\n0.95\n0.95\n\n\n2\n0.1\n0.85\n25\n50\n37.5\n0.79\n0.79\n\n\n3\n0.1\n0.85\n30\n50\n37.5\n0.79\n0.69\n\n\n4\n0.1\n0.85\n25\n45\n37.5\n0.69\n0.79\n\n\n5\n0.2\n0.70\n25\n75\n50.0\n0.95\n0.95\n\n\n6\n0.4\n0.40\n25\n75\n50.0\n0.95\n0.95\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIn all scenarios: \\(\\sigma_0 = \\sigma_1 = 15\\)\nSimulated continuous values were dichotomised using a cut-off that maximised sensitivity and specificity"
  },
  {
    "objectID": "SVEPM_slides.html#application-of-the-model",
    "href": "SVEPM_slides.html#application-of-the-model",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Application of the model",
    "text": "Application of the model\n\nEach scenario was simulated 1,500 times\nData from each simulation used as model input\nMCMC draws for each parameter analysed and presented"
  },
  {
    "objectID": "SVEPM_slides.html#parameter-estimation-tau_1-and-tau_2",
    "href": "SVEPM_slides.html#parameter-estimation-tau_1-and-tau_2",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Parameter estimation: \\(\\tau_1\\) and \\(\\tau_2\\)",
    "text": "Parameter estimation: \\(\\tau_1\\) and \\(\\tau_2\\)\n\nBias is close to 0 in all scenarios with the continuous model and in scenarios 1-4 with the discrete model.\nPoorly estimated with the discrete model in scenarios 5 and 6.\nPosterior variance varies across scenarios but is consistently lower with the continuous model."
  },
  {
    "objectID": "SVEPM_slides.html#parameter-estimation-mu_0-and-mu_1",
    "href": "SVEPM_slides.html#parameter-estimation-mu_0-and-mu_1",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Parameter estimation: \\(\\mu_0\\) and \\(\\mu_1\\)",
    "text": "Parameter estimation: \\(\\mu_0\\) and \\(\\mu_1\\)\n\n\\(\\mu_0\\) accurately estimated for all scenarios\n\\(\\mu_1\\) consistently underestimated across scenarios\nThe standard deviations follow the same pattern as before:\n\n\\(\\nearrow\\) when \\(\\mu_0\\) and \\(\\mu_1\\) are closer\n\\(\\nearrow\\) with \\(\\searrow\\) time correlation in test results"
  },
  {
    "objectID": "SVEPM_slides.html#bvd-in-brittany",
    "href": "SVEPM_slides.html#bvd-in-brittany",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "BVD in Brittany",
    "text": "BVD in Brittany\n\nInfection by the Bovine Viral Diarrhoea Virus (BVDV):\n\nMajor impact in newly infected herds (abortions, reproductive problems, mortality)\nInfection mostly transmitted by persistently infected (PI) animals: infected in utero, massive lifelong excretion of the virus, no antibody production\n\nBrittany, a French region (~27 000 km\\(^2\\)) is divided into 4 départements:\n\nCôtes d’Armor (22), Finistère (29), Ille-et-Vilaine (35), Morbihan (56)\n\nBVD surveillance programme in Brittany, since 2014\n\nBTM tested in every herd, every 3 months\n2 antibody ELISA tests used alternately"
  },
  {
    "objectID": "SVEPM_slides.html#application-of-the-model-1",
    "href": "SVEPM_slides.html#application-of-the-model-1",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Application of the model",
    "text": "Application of the model\n\nSurveillance data collected from 2014 to 2020 used as model input\nModel run separately for each département and each year\n\nModels for 2014: weakly informative priors\nFrom 2015 onward: posterior estimates from the previous year used as priors for the current year\n\nMCMC draws for each parameter analysed and presented"
  },
  {
    "objectID": "SVEPM_slides.html#test-characteristics-variation-with-time",
    "href": "SVEPM_slides.html#test-characteristics-variation-with-time",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Test characteristics: variation with time",
    "text": "Test characteristics: variation with time\n\n\n\nFinistère taken as an example for years 2014 to 2020\n\nBTMab2 performs much better than BTMab1\nLittle variation with time\n\nTest characteristics remain stable between years"
  },
  {
    "objectID": "SVEPM_slides.html#test-characteristics-variation-with-département",
    "href": "SVEPM_slides.html#test-characteristics-variation-with-département",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Test characteristics: variation with département",
    "text": "Test characteristics: variation with département\n\n2020 taken as an example\n\nLittle variation in estimated test characteristics between départements"
  },
  {
    "objectID": "SVEPM_slides.html#dynamics-of-seroconversion",
    "href": "SVEPM_slides.html#dynamics-of-seroconversion",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Dynamics of seroconversion",
    "text": "Dynamics of seroconversion\n\n\n\nMean monthly probability of seroconversion (\\(\\tau_1\\)) varied between 1% and 7%\n\nSmall and stable between 1% and 3% in Finistère and Morbihan\nHigher and more variable between 3 and 7% in Finistère\n\nMean monthly probability of remaining seropositive (\\(\\tau_2\\)) varied between 80% and 95% :\n\nMore variable and lower values in Ille-et-Vilaine"
  },
  {
    "objectID": "SVEPM_slides.html#hmms-for-modelling-surveillance-data",
    "href": "SVEPM_slides.html#hmms-for-modelling-surveillance-data",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "HMMs for modelling surveillance data",
    "text": "HMMs for modelling surveillance data\n\nA statistical framework well-suited for modelling test results from surveillance programmes, which are typically imperfect and time-correlated\nKeeping test results continuous improves estimation performance when evaluated on simulated data:\n\nCompared to using binary test results\nWhen the underlying distributions for negative/positive results are further apart\nWhen temporal correlation increases\n\nTemporal correlation in BVDV seropositivity in Brittany (\\(\\tau_1 \\approx 0.05\\), \\(\\tau_2 \\approx 0.9\\))\n\nHerds are unlikely to change status between tests conducted every 3 months\nTherefore, tests performed 3 months apart often measure the same underlying status\nThis enables the evaluation of test characteristics without a gold standard"
  },
  {
    "objectID": "SVEPM_slides.html#challenges-and-future-directions",
    "href": "SVEPM_slides.html#challenges-and-future-directions",
    "title": "Evaluation and application of a Bayesian Hidden Markov Model to the surveillance of BVD",
    "section": "Challenges and future directions",
    "text": "Challenges and future directions\n\nWhen prevalence is low:\n\nParameter identification is challenging with weakly informative priors\nThis can be addressed by using priors derived from early-phase control data or other surveillance programmes\n\nPotential future work:\n\nIncorporating risk factors for new infection/seroconversion is conceptually straightforward\nModelling within-herd prevalence to predict the distribution of test results in positive herds"
  }
]